Nasdaq · Healthcare
Moderna, Inc. (MRNA)
As-reported financials and recent SEC filings for Moderna, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.94B
Net income
$-2.82B
Net margin
-145.2%
Diluted EPS
$-7.26
ROE
-32.6%
P/E (TTM)
—
Market cap
$26.69B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| Gross profit | $1.08B | $1.77B | $2.15B | $13.85B | $15.85B |
| Operating income | $-3.07B | $-3.94B | $-4.24B | $9.42B | $13.30B |
| Net income | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B |
| Diluted EPS | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-18
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-15
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →1442026-06-04
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →Go deeper on MRNA
Search Moderna, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.